Source: CureToday articles
Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for patients with hormone receptor-positive metastatic breast cancer.
Recent Content
- Pre-Treatment Baseline Screening for Breast Cancer–Related Lymphedema
- Dosing of PAS-004 Begins in Patients in MAPK-Driven Tumors
- Barriers to Bridging Clinical Trial Data to Routine Pharmacy Practice
- Enhancing Patient Care Through Multidisciplinary Team Collaboration in Management of NSCLC
- CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma
- Asembia AXS25: Navigating the Future of Cell and Gene Therapies
- Asembia AXS25: Addressing Health Equity in Specialty Pharmacy Services
- Recapping Every FDA Approval Announced in April for Cancer Care
- Understanding Cancer Changes and Testing: How Testing Guides Your Metastatic Breast Cancer Treatment
- FDA Approves Atzumi, Nasal Powder Formulation of DHE, for Acute Treatment of Migraine